JP2002504491A5 - - Google Patents

Download PDF

Info

Publication number
JP2002504491A5
JP2002504491A5 JP2000532434A JP2000532434A JP2002504491A5 JP 2002504491 A5 JP2002504491 A5 JP 2002504491A5 JP 2000532434 A JP2000532434 A JP 2000532434A JP 2000532434 A JP2000532434 A JP 2000532434A JP 2002504491 A5 JP2002504491 A5 JP 2002504491A5
Authority
JP
Japan
Prior art keywords
peptide analog
residue
residues
chain
human insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000532434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002504491A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/003915 external-priority patent/WO1999042482A1/en
Publication of JP2002504491A publication Critical patent/JP2002504491A/ja
Publication of JP2002504491A5 publication Critical patent/JP2002504491A5/ja
Pending legal-status Critical Current

Links

JP2000532434A 1998-02-23 1999-02-23 インスリンのペプチドアナログを使用した糖尿病の処置のための方法 Pending JP2002504491A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2815698A 1998-02-23 1998-02-23
US09/028,156 1998-02-23
PCT/US1999/003915 WO1999042482A1 (en) 1998-02-23 1999-02-23 Methods for treatment of diabetes using peptide analogues of insulin

Publications (2)

Publication Number Publication Date
JP2002504491A JP2002504491A (ja) 2002-02-12
JP2002504491A5 true JP2002504491A5 (ru) 2006-03-23

Family

ID=21841884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000532434A Pending JP2002504491A (ja) 1998-02-23 1999-02-23 インスリンのペプチドアナログを使用した糖尿病の処置のための方法

Country Status (20)

Country Link
US (1) US6197926B1 (ru)
EP (1) EP1056776A1 (ru)
JP (1) JP2002504491A (ru)
KR (1) KR20010041238A (ru)
CN (1) CN1241942C (ru)
AP (1) AP2000001888A0 (ru)
AU (1) AU741037B2 (ru)
BR (1) BR9908178A (ru)
CA (1) CA2321929A1 (ru)
EA (1) EA003944B1 (ru)
HU (1) HUP0100928A3 (ru)
ID (1) ID26788A (ru)
IL (1) IL137904A0 (ru)
NO (1) NO20004198L (ru)
NZ (1) NZ506447A (ru)
OA (1) OA11453A (ru)
PL (1) PL342517A1 (ru)
SK (1) SK12412000A3 (ru)
TR (1) TR200003048T2 (ru)
WO (1) WO1999042482A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) * 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
ATE367816T1 (de) * 2000-05-12 2007-08-15 Univ Oregon Health & Science Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
CN100582085C (zh) 2002-10-10 2010-01-20 耶达研究及发展有限公司 脂肪醇的碱性酯及它们作为抗炎药或免疫调节剂的用途
WO2004110373A2 (en) * 2003-06-02 2004-12-23 Mercia Pharma, Inc. Therapeutic vaccine compositions for the treatment of type 1 diabetes
EP1786465A4 (en) * 2004-07-30 2009-01-21 Univ Oregon Health & Science METHODS FOR DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DK2229407T3 (en) 2008-01-09 2017-02-27 Sanofi Aventis Deutschland NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
CA2747490C (en) * 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
PT2498802E (pt) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
US20110311536A1 (en) * 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation アミド系インスリンプロドラッグ
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
CN111925420B (zh) * 2019-12-11 2022-04-01 山东大学 一种多肽作为嗅觉受体Olfr109激动剂配体的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
JPH11509195A (ja) * 1995-06-30 1999-08-17 ノボ ノルディスク アクティーゼルスカブ 糖尿病の特徴を有する疾患の予防

Similar Documents

Publication Publication Date Title
JP2002504491A5 (ru)
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
NO923142D0 (no) Cykliske peptider og anvendelse derav
MXPA02002977A (es) Analogos de hormona paratiroidea para el tratamiento de la osteoporosis.
AU2003264514A8 (en) Wt1 substitution peptides
GB9930882D0 (en) GLP-2 formulations
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
YU71395A (sh) Acilovani analozi insulina
JP2002509854A5 (ru)
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
MXPA05002991A (es) Analogos de ghrh.
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DK0482013T3 (da) Ikke-glycolyserede humant interleukin-3 analoge proteiner
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
CA2208274A1 (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
AU2002330289A1 (en) Preparation of a therapeutic composition
WO2004009625A3 (en) PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES
GR3031927T3 (en) Cysteine depleted il-6 muteins
NZ508816A (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
ATE323724T1 (de) Mpl-liganden analoga
JP2004505616A5 (ru)
DE60036199D1 (de) Proteaseresistente flint-analoge
AU1464488A (en) Human rhinovirus peptides
MY120083A (en) Process for the preparation of cyclo(asp-dphe-nmeval-arg-gly)
MXPA01003340A (es) Composiciones farmaceuticas en base a alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh.